Q4 2017 EPS Estimates for BiondVax Pharmaceuticals Ltd. (BVXV) Boosted by Zacks Investment Research
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) – Stock analysts at Zacks Investment Research raised their Q4 2017 EPS estimates for shares of BiondVax Pharmaceuticals in a report released on Tuesday. Zacks Investment Research analyst D. Bautz now anticipates that the company will earn $0.00 per share for the quarter, up from their prior forecast of ($0.01).
Separately, ValuEngine cut shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.
BiondVax Pharmaceuticals (BVXV) traded down $0.21 on Thursday, hitting $4.99. 20,800 shares of the company traded hands, compared to its average volume of 43,768. BiondVax Pharmaceuticals has a twelve month low of $3.04 and a twelve month high of $10.75.
BiondVax Pharmaceuticals Company Profile
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.